1. Introduction {#sec1}
===============

Renal cell carcinoma (RCC) constitutes 90% of all renal malignancies, and there is an increasing trend in the incidence of RCC worldwide. Clear cell RCC (ccRCC) is the most common subtype of RCC, comprising approximately 80% of all RCC \[[@B1]\]. The most commonly known risk factors for RCC include age, gender, smoking, hypertension, and obesity \[[@B2]\]. Other kidney diseases such as Von Hippel-Lindau/VHL an autosomal dominant hereditary disorder and end-stage renal failure also contribute to RCC \[[@B3], [@B4]\]. The incidence of obesity has also increased worldwide. In Malaysia, a 10-year survey showed that there was a significant increase in the overweight and obese population due to an inactive lifestyle \[[@B5]\]. Considering the obesity statistics, the overall hypothesis of the present study is that there is a causative link between obesity and RCC development.

Leptin is one of the adipokines produced from adipose tissue. Its expression is of research interest due to its role in obesity and cancer \[[@B6]\]. Leptin maintains the homeostasis of the human body by lowering the caloric intake and increasing energy expenditure as illustrated in [Figure 1](#fig1){ref-type="fig"} \[[@B7]\]. In the process of leptin homeostasis, other pathways are activated, namely, the JAK2/STAT3, PI3K, and AKT pathways. These pathways are responsible for increasing the expression of antiapoptotic protein (X-linked inhibitor of apoptosis protein/XIAP), increasing systematic inflammation (tumor necrosis factor-*α*/TNF-*α*; interleukin-6/IL-6), and promoting angiogenic factors (vascular endothelial growth factor/VEGF and hypoxia-inducible factor-1*α*/HIF-1*α*) which foster cancer cell survival, proliferation, and migration. These factors have shown a significant association with leptin in breast cancer \[[@B8], [@B9]\] and colorectal cancer \[[@B10], [@B11]\]. Reports indicated that the presence of high serum leptin leads to the progression of cancer. To date, serum leptin has been the focus of studies investigating its contribution in the development of RCC \[[@B12], [@B13]\], with some studies indicating that high serum leptin is associated with the development and progression of RCC \[[@B14]\], while other studies showed no connection between leptin and the development and advancement of RCC \[[@B15]\].

Leptin receptor is a protein that is found extensively in the hypothalamus of the human brain and also in other peripheral tissues such as the liver, gall bladder, and colon \[[@B16]\]. Several studies have been carried out to correlate enhanced leptin receptor levels with carcinogenesis and cancer progression \[[@B17]--[@B19]\]. A study by Ishikawa and colleagues confirmed that upregulated leptin receptor expression promotes carcinogenesis and metastasis of breast cancer \[[@B9], [@B20]\]. However, there was no study on leptin receptor in association with ccRCC.

Studies on the prognostic value of leptin and leptin receptor in ccRCC are very limited especially studies using immunohistochemistry (IHC). In recent years, the number of molecular-based assays has increased but histopathology remains the gold standard for most diagnostic and therapeutic decisions. IHC is a globally available tool that complements histopathological analysis by detecting protein expression \[[@B21]\]. In the present study, we aim to measure the expressions of leptin and leptin receptor in ccRCC and adjacent non-cancerous tissue to determine the prognostic significance of these two proteins using IHC methods \[[@B22]\].

2. Methodology {#sec2}
==============

2.1. Subject Recruitment and Study Samples {#sec2.1}
------------------------------------------

All samples were from patients undergoing radical nephrectomy at University Malaya Medical Centre (UMMC) between the years 2011 and 2018. The study was approved by the Ethics Committee (ID no.: 20166-2611) of the UMMC. Informed consent was obtained from all subjects whose samples were used in this study as per protocol.

2.2. Immunohistochemistry {#sec2.2}
-------------------------

Formalin-fixed paraffin-embedded (FFPE) samples were sectioned onto Superfrost Plus slides at 4 *μ*m, dewaxed in xylene, and rehydrated in several changes of alcohol to Tris-buffered saline with Tween 20 (TBST). Antigen retrieval was performed in sodium citrate buffer (pH 6 at 95°C for 20 minutes), followed by washing with TBST and blocking for 15 minutes with 3% hydrogen peroxide. Primary antibodies were obtained from Santa Cruz Biotechnology (Dallas, USA). Leptin (anti-rabbit; \#sc-842; 1 : 200) and leptin receptor (anti-rabbit; \#sc-8325; 1 : 100) was added to sections to bind with the protein of interest. They were placed in a humidity chamber overnight at 4°C, followed by 45 minutes of incubation with polymer as secondary antibody at room temperature. After washing with TBST, 3,3′-diaminobenzidine (DAB) staining was performed, followed by counterstaining with hematoxylin, dehydration, and mounting in Depex. All the slides were scanned using Aperio Image Scanning by Leica Biosystem at 40x magnification. The immunopositivity score was reported manually and also as a ratio of positive pixels \[[@B23]\]. The cut-off points were determined by using the formula below: $$\begin{matrix}
{\text{Protein expression ratio} = \frac{\text{Positive pixels of ccRCC tissue}}{\text{Positive pixels of adjacent tissue}}} \\
\end{matrix}$$

A cut-off point of ≤0.75 was considered low expression, 0.76--1.24 was considered showing no differential expression, and ≥1.25 was considered showing increased differential expression for either proteins \[[@B24]\].

2.3. Statistical Analysis {#sec2.3}
-------------------------

All data were presented as a percentage, and SPSS20.0 software was used for statistical analysis. Quantitative data were analyzed by the Chi-square test, and the Kaplan-Meier test was carried out for survival analysis. *p* \< 0.05 was considered statistically significant \[[@B23]\].

3. Results {#sec3}
==========

Tissue samples for this study were obtained from patients who have undergone nephrectomy for RCC with subsequent histopathological confirmation of ccRCC. Based on the World Health Organisation (WHO) criteria, BMI of 18.5-24.9 is considered normal and BMI of 30--39.9 is considered obese \[[@B25]\]. Since the study was focused only on non-obese versus obese patients, underweight subjects (BMI of \<18) and overweight subjects (BMI of 25--29.9) were excluded. The pathological diagnosis of ccRCC was confirmed by a pathologist in all samples used in this study. The clinical information for all patients was retrieved from the medical records of the UMMC.

The samples included Stage I (*n* = 23), Stage II (*n* = 14), Stage III (*n* = 12), and Stage IV (*n* = 11) ccRCC according to clinical stage. Among the patients included in this cohort, 26 have normal BMI and 34 were obese, based on WHO criteria. The demographics of the recruited ccRCC patients are shown in [Table 1](#tab1){ref-type="table"}. In [Table 2](#tab2){ref-type="table"}, demographic data with leptin and leptin receptor expressions are shown.

Quantitative analysis of the expression intensity revealed that leptin overall positivity (cytoplasm and membrane) was not significantly different in adjacent non-cancerous kidney compared to ccRCC tissue (*p* \> 0.05). There was also no difference for nuclear positivity in adjacent noncancer kidney compared to ccRCC (*p* \> 0.05) as shown in [Figure 2](#fig2){ref-type="fig"}. Quantitative analysis of the expression intensity revealed there was no significant difference in adjacent non-cancerous kidney compared to ccRCC tissue for leptin receptor overall positivity and in adjacent non-cancerous kidney compared to ccRCC tissue for leptin receptor nuclear positivity (*p* \> 0.05). These results are shown in [Figure 3](#fig3){ref-type="fig"}.

The survival rate of recruited subjects was determined by using the Kaplan-Meier analysis based on overall survival (OS), recurrent-free survival (RFS), and disease-specific survival (DSS) ([Figure 4](#fig4){ref-type="fig"}). A cut-off point of ≥1.25 was used as a high expression in leptin overall expression and nuclear expression for OS, RFS, and DSS. Patients grouped as leptin high overall expression and nuclear expressions were not significantly associated with worse survival prognosis except for OS which was statistically significant with a *p* value of 0.021 ([Figure 4(d)](#fig4){ref-type="fig"}). A cut-off point of ≥1.25 was used as a high expression in leptin receptor overall expression and nuclear expression for OS, RFS, and DSS. Patients grouped as leptin receptor high overall expression and nuclear expressions were not significantly associated with worse survival prognosis. These data are shown in [Figure 5](#fig5){ref-type="fig"}.

4. Discussion {#sec4}
=============

Leptin and leptin receptor proteins are primarily secreted by adipose tissue, with the major purpose being to balance the energy expenditure and caloric intake of the human body. The activation of these proteins can also activate pathways such as STAT3/JAK2, P13K, and AKT that promote the proliferation, progression, and survival of cancerous cells \[[@B26]\]. Examples of molecular changes include the antiapoptotic protein XIAP whose expression is elevated in many cancer types and participate in the release of proapoptotic proteins \[[@B27]\]; inflammation mediators such as TNF-*α*, IL-6, transforming growth factor-*β*, and IL-10 have been shown to participate in both the initiation and progression of cancer \[[@B28]\]; and the VEGF signaling pathway plays pivotal roles in regulating tumour angiogenesis \[[@B29]\]. Several studies have reported that large amounts of adipose tissue in the body can lead to cancer progression; for example, obese patients with breast cancer, colorectal cancer, and endometrial cancer exhibit poorer prognosis \[[@B30]--[@B32]\].

This preliminary study was carried out to evaluate the relationship between leptin and its receptor in the progression of ccRCC in a small Malaysian cohort of normal weight and obese ccRCC patients. The findings from this cohort showed that leptin and leptin receptor were not associated with cancer progression in ccRCC tissue. The overall and nuclear expressions of leptin and leptin receptor were not significantly different in ccRCC compared to the adjacent non-cancerous kidney tissue. In addition, overall and nuclear expressions were not significantly associated with pathological stage and grade or BMI for both leptin and leptin receptor. Therefore, the results obtained from this IHC study indicated that leptin and leptin receptor might not be valuable biomarkers for disease progression of ccRCC. The tissue expressions of leptin and its receptor were not predictive of the DSS or RFS among ccRCC patients, but interestingly, high nuclear expression of leptin was associated with worse OS. The contributing factors leading to the association with adverse OS are still unclear, and further studies may be required to confirm this association.

Studies on leptin and leptin receptor, in RCC, have also been performed using other modalities such as serology studies and molecular techniques investigating gene expression. In a gene polymorphism study by Azza et al., in a cohort of 123 RCC and 50 control patients, leptin receptor was considered a potential risk factor for a bad prognosis such as advanced tumour stage, higher nuclear grade, and shorter survival \[[@B33]\]. The results of another gene study carried out specifically in ccRCC by Hui-Jun et al. (77 ccRCC; 161 healthy controls) suggested that the combination of polymorphisms of Lys109Arg and Gln223Arg in leptin receptor can act as a diagnostic and prognostic factor for ccRCC \[[@B34]\].

Serum leptin studies have been carried out in the evaluation of early detection of RCC. Akio et al. evaluated leptin and leptin receptor in the serum of 57 RCC patients. They concluded that both these proteins could have a key role in the invasion of RCC and could be a valuable predictor of prognosis \[[@B35]\]. In comparison, other researchers believed that leptin and its receptor were not valuable biomarkers in the development of this fatal disease. A study by Horiguchi et al. determined that serum leptin was not a useful biomarker for RCC in both males and females \[[@B35]\]. Another researcher found that leptin levels had an inverse association with the risk of RCC \[[@B14]\]. Thus, there are quite disparate outcomes of studies, and this was what prompted our investigation using the IHC technique.

The uniqueness of our current study is that it focused on IHC expression of leptin and its receptor specifically in ccRCC, and a comparison of the protein expressions was carried out between normal and obese patients. We believe that there is valuable information hidden in tissue samples that may contribute tremendously to personalised or precision medicine.

5. Conclusion {#sec5}
=============

In conclusion, there were no differential expression patterns of leptin and leptin receptor in ccRCC tissue and adjacent non-cancerous kidney, between non-obese and obese patients. There was also no association with tumour characteristics of ccRCC patients. As a result, both proteins may not have a significant contribution in the formation or progression of ccRCC. However, nuclear expression of leptin was significantly associated with OS in these patients. This may warrant further investigation to elucidate the exact contributing factor for this. There may be involvement of other adipokines secreted from the fat tissue in tumour progression of ccRCC, and further studies should be carried out on those adipokines with a larger patient cohort to identify novel biomarkers for RCC.
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![Homeostasis of leptin. Description on the role of leptin in energy expenditure and food intake.](BMRI2020-3682086.001){#fig1}

![Leptin overall and nuclear immunohistochemistry. (a) Negative control. (b) Positive liver control (cytoplasm positivity indicated by the red arrow; the nucleus remains unstained as indicated by the blue arrow). (c) Adjacent normal kidney (cytoplasm positivity indicated by the red arrow; the nucleus remains unstained as indicated by the blue arrow). (d) ccRCC (focal cytoplasmic positivity indicated by the red arrow; some of the ccRCC nucleus stained positive as indicated by the blue arrow). (e) Overall positive pixel. (f) Nuclear positive pixel. There was no differential overall and nuclear expression intensity of leptin in ccRCC compared with paired normal kidney.](BMRI2020-3682086.002){#fig2}

![Leptin receptor overall and nuclear immunohistochemistry. (a) Negative control. (b) Positive liver control (cytoplasm positivity indicated by the red arrow; the nucleus remains unstained as indicated by the blue arrow). (c) Adjacent normal kidney (cytoplasm positivity indicated by the red arrow; the nucleus remains unstained as indicated by the blue arrow). (d) ccRCC (focal weak cytoplasmic positivity indicated by the red arrow, some of the ccRCC nucleus stained positive as indicated by the blue arrow). (e) Overall positive pixel. (f) Nuclear positive pixel. There was no differential overall and nuclear expression intensity of the leptin receptor in ccRCC compared with paired normal kidney.](BMRI2020-3682086.003){#fig3}

![Survival rate of ccRCC associated with leptin overall and nuclear expression. (a) OS associated with leptin overall expression, (b) RFS associated with leptin overall expression, and (c) DSS associated with leptin overall expression, (d) OS associated with leptin nuclear expression, (e) RFS associated with leptin nuclear expression, and (f) DSS associated with leptin nuclear expression.](BMRI2020-3682086.004){#fig4}

![Survival rate of ccRCC associated with leptin receptor overall and nuclear expression. (a) OS associated with leptin receptor overall expression, (b) RFS associated with leptin receptor overall expression, and (c) DSS associated with leptin receptor overall expression. (d) OS associated with leptin receptor nuclear expression, (e) RFS associated with leptin receptor nuclear expression, and (f) DSS associated with leptin receptor nuclear expression.](BMRI2020-3682086.005){#fig5}

###### 

Demographic data of study cohort.

  Variable                 Subjects (*n* = 60)
  ------------------------ ---------------------
  Mean age (range) years   60.5 (30-82)
  Gender (%)               
   Male                    42 (70.0)
   Female                  18 (30.0)
  Ethnicity (%)            
   Malay                   19 (31.7)
   Chinese                 29 (48.3)
   Indian                  12 (20.0)
  Tumour side (%)          
   Right                   27 (45.0)
   Left                    33 (55.0)
  BMI (%)                  
   Normal                  26 (41.2)
   Obese                   34 (56.7)
  Mean BMI (range)         27.1 (16.2-40.9)
  T stage (%)              
   1                       29 (48.3)
   2                       13 (21.7)
   3                       17 (28.3)
   4                       1 (1.7)
  N stage (%)              
   N0                      52 (86.7)
   N1                      8 (13.3)
  Metastases (%)           
   M0                      48 (80.0)
   M1                      12 (20.0)
  Clinical stage (%)       
   Stage I                 23 (38.3)
   Stage II                14 (23.3)
   Stage III               12 (20.0)
   Stage IV                11 (18.3)
  Fuhrman grade (%)        
   Grades 1-2              40 (66.7)
   Grades 3-4              20 (33.3)

###### 

Expressions of leptin and leptin receptor in tumour tissue with correlation to cohort characteristics and tumour features.

  Variables        Leptin   Leptin receptor                                                                     
  ---------------- -------- ----------------- ------- ------ ------ ------- ------ ------ ------- ------ ------ -------
  BMI                                                                                                           
   Normal          10.0     16.7              0.097   20.0   13.3   0.384   18.3   11.7   0.760   21.7   18.3   0.426
   Obese           26.7     15.0              25.0    28.3   21.7   16.7    20.0   26.7                         
  T stage                                                                                                       
   1               20.0     16.7              0.342   18.3   25.0   0.414   15.0   13.3   0.212   21.7   18.3   0.414
   2               11.7     3.3               15.0    5.0    8.3    8.3     8.3    11.7                         
   3               5.0      11.7              10.0    11.7   15.0   6.7     11.7   13.3                         
   4               0.0      0.0               1.7     0.0    1.7    0.0     0.0    1.7                          
  N stage                                                                                                       
   N0              33.3     26.7              0.523   41.7   33.3   0.084   38.3   25.0   0.374   36.7   36.7   0.483
   N1              3.3      5.0               3.3     8.3    1.7    3.3     5.0    8.3                          
  Metastasis                                                                                                    
   M0              30.0     28.3              0.587   33.3   33.3   0.582   28.3   20.0   0.814   35.0   36.7   0.836
   M1              6.7      3.3               11.7    8.3    11.7   8.3     6.7    8.3                          
  Clinical stage                                                                                                
   I               18.3     11.7              0.242   16.7   18.3   0.683   13.3   6.7    0.859   20.0   13.3   0.420
   II              11.7     6.7               15.0    5.0    8.3    10.0    8.3    13.3                         
   III             3.3      10.0              5.0     8.3    10.0   3.3     6.7    11.7                         
   IV              3.3      3.3               8.3     10.0   8.3    8.3     6.7    6.7                          
  Grade                                                                                                         
   Grades 1-2      28.3     18.3              0.188   28.3   30.0   0.496   26.7   18.3   0.912   26.7   28.3   0.922
   Grades 3-4      8.3      13.3              16.7    11.7   13.3   10.0    15.0   16.7                         
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